News
ERC Consolidator Grant for Peter Walentek
European Union funds research into the adaptability of tissues
Second Funding Period for NephGen!
The DFG confirmed in their latest press release that the CRC 1453 will receive funding for a second...
KFO 201
Polycystic Disease – From Model Organisms to Novel Therapies
Funding: 2008 - 2018
Welcome
Polycystic kidney disease (PKD) is a group of diseases characterized by dilated or cystic tubular segments of the kidney accompanied by a wide spectrum of abnormalities in other organs. Cystic tubules fail to perform their physiological function properly, resulting in fluid retention, high blood pressure and kidney failure requiring dialysis or transplantation. Over the last decade, more than 20 genes have been identified that cause polycystic kidney disease. The most common form, autosomal dominant polycystic kidney disease (ADPKD), affects between 1/500 and 1/1000 people. PKD is an important health care problem. It is responsible for ~5% of all individuals with end stage kidney failure.
The Clinical Research Unit 201 employs a multidisciplinary approach to bridge the gap between experimental research at the molecular level and optimal patient care.